Abstract

The Antibody Development Facility provides investigators with custom designed monoclonal antibodies. In most, if not all cases, these are necessary reagents that are not commercially available. Services provided include: a) the design of antigens, immunization and screening strategies b) hybridoma cell line production via traditional methods, c) optimization of existing hybridoma cell lines by selection cloning d) production of monoclonal antibodies in species other than mice, e) services to wean hybridoma cell lines off selection media and into a variety of basal and serum free media for use in mini-bioreactors, immune precipitation or in vivo studies, f) cloning, expression and engineering of single chain antibody variable fragments (scFvs) or scFvs containing biological reporter molecules such as green fluorescent protein and g) the selection of antigen specific antibodies and their fragments from phage display libraries. This application requests continued support for a resource which continues to fulfill an essential role for peer reviewed research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-30
Application #
6728860
Study Section
Subcommittee G - Education (NCI)
Project Start
2003-03-12
Project End
2007-12-31
Budget Start
2003-03-12
Budget End
2003-12-31
Support Year
30
Fiscal Year
2003
Total Cost
$291,244
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications